Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries

Circulation

Volumn 99, Issue 22, 1999, Pages 2914-2920

  Padmanabhan, Neal ^a,c   Jardine, Alan G ^a   McGrath, John C ^b   Connell, John M C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Gardiner Institute   (United Kingdom)

Author keywords

Angiotensin; Arteries; Chymase

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; CHYMASE; CHYMOSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRILAT; NORADRENALIN;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE BLOOD VESSEL; SMOOTH MUSCLE CONTRACTILITY; VASCULAR SMOOTH MUSCLE;

EID: 0033535979     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.22.2914     Document Type: Article

References (29)

1. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive treatment with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982; 4:966-972.
2. Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers J-M, Pouleur H. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohumoral activation and effects of ibopamine therapy during long term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 1994;73:488-493.
3. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
4. Arakawa K. Serine protease angiotensin II systems. J Hypertens. 1996; 14(suppl):S3-S7.
5. 12)-angiotensin-I. Hypertension. 1994;23:857-860.
6. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertension. 1984; 2:277-284.
7. Balcells E, Meng QC, Hageman GR, Palmer RW, Durand JN, Dell'Italia LJ. Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Am J Physiol. 1996;271:H417-H421.
8. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol. 1993;62:207-210.
9. Lindpaintner K, Jin MW, Niedermaier N, Wilhelm MJ, Ganten D. Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ Res. 1990;67:564-573.
10. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
11. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, Roden RL, Peacock SJ, Groves BN, Raynolds MV, Bristow MR, Perryman MB. Angiotensin II formation in the intact human heart. J Clin Invest. 1995;95:1490-1498.
12. Bund SJ, Aalkjaer C, Heagerty AM, Leckie B, Lever AF. The contractile effects of porcine tetradecapeptide renin substrate in human resistance vessels: evidence of activation by vascular wall renin and serine protease. J Hypertens. 1989;7:741-746.
13. Aalkjaer C, Pederson EB, Danielson H, Mulvany MJ. Morphological and functional characteristics of isolated resistance vessels in advanced uraemia. Clin Sci. 1986;71:657-663.
14. Mulvany MJ, Aalkjaer C. Structure and function of small arteries. Physiol Rev. 1990;4:922-961.
15. Waldeck K, Lindberg BF, Persson K, Anderson KE. Characterisation of angiotensin-II formation in human isolated bladder by selective inhibitors of angiotensin converting enzyme and human chymase. Br J Pharm. 1997;121:1081-1086.
16. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci. 1994;87:567-574.
17. Sudhir K, Chou TM, Hutchison SJ, Chatterjee K. Coronary vasodilation induced by angiotensin-converting enzyme inhibition in vivo: differential contribution of nitric oxide and bradykinin in conductance and resistance arteries. Circulation. 1996;93:1734-1739.
18. Kuga T, Mohri M, Egashira K, Hirakawa J, Tagawa T, Shimokawa H, Takeshita A. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol. 1997;30:108-112.
19. Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, Husain A. Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 1990;266:17173-17179.
20. Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase in the human heart. J Biol Chem. 1991;266:19192-19197.
21. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:1269-1281.
22. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
23. Berk BC, Vekstein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension. 1989;13:305-314.
24. Clozel JS, Hess P, Michael C, Schietinger K, Baumgartner HR. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs. Hypertension. 1991;18(suppl II):II-55-II-59.
25. Shiota N, Okunishi H, Fukamizu A, Sakonjo H, Kikumori N, Nishimura T, Nakagawa T, Murakami M. Activation of two angiotensin-generating systems in the balloon injured artery. FEBS Lett. 1993;323:239-242.
26. Halpern W, Osol G, Coy GS. Mechanical behaviour of pressurised in vitro pre-arteriolar vessels determined with a video system. Ann Biomed Eng. 1984;12:463-479.
27. Aldigier JC, Huang H, Dalmay F, Lartigue M, Baussant T, Chassain AP, Leroux-Robert C, Galen FX. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol. 1993;21:289-295.
28. Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, Tanaka H, Shindo M, Arakawa K. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens. 1994;12: 1177-1181.
29. Urabe Y, Ideishi M, Sasguri M, Ikeda M, Arakawa K. Beneficial effects of a serine protease inhibitor in peripheral vascular disease. Am J Cardiol. 1993;72:218-222.